News - AstraZeneca, Financial

Filter

Current filters:

AstraZenecaFinancial

Popular Filters

1 to 25 of 51 results

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca first quarter sales flat, but beat forecasts

24-04-2014

Anglo-Swedish drug major AstraZeneca this morning posted first-quarter 2014 financials, revealed sales…

AstraZenecaFinancialPharmaceutical

AstraZeneca 4th-qtr profits plunge 26% on generic woes

AstraZeneca 4th-qtr profits plunge 26% on generic woes

06-02-2014

Increasing generic competition took its toll on Anglo-Swedish drug major AstraZeneca, which this morning…

AstraZenecaFinancialPharmaceutical

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

Hutchison China MediTech upgraded by Panmure

30-01-2014

In a new report on Chinese pharmaceutical company Hutchison China MediTech, Panmure Gordon analyst Savvas…

AstraZenecaFinancialHutchison MediTechOncologyPharmaceuticalResearchvolitinib

AstraZeneca expects 2017 revenues to be broadly in line with 2013 revenues

AstraZeneca expects 2017 revenues to be broadly in line with 2013 revenues

14-01-2014

Anglo-Swedish drug major AstraZeneca (LSE: AZN) will provide an update on its business plans at the JP…

AstraZenecaFinancialPharmaceuticalUK

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

AstraZeneca wins damages from Apotex

AstraZeneca wins damages from Apotex

04-12-2013

Anglo-Swedish drug major AstraZeneca this morning said it welcomed the US District Court for the Southern…

ApotexAstraZenecaFinancialGastro-intestinalsGenericsNexium I.V.North AmericaPatentsPrilosec

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

AstraZeneca 3rd-qtr fails to meet expectations

AstraZeneca 3rd-qtr fails to meet expectations

31-10-2013

AstraZeneca said its third quarter revenue declined due to the ongoing impact from products with recent…

AstraZenecaFinancialPharmaceutical

Is downgrade cycle levelling off a signal to buy AstraZeneca stock?

12-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) shares have been weak, as defensive stocks retrench from…

AstraZenecaFinancialPharmaceutical

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

AstraZeneca records fall in 2nd-qtr revenue but 21% rise in China sales

01-08-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reported second-quarter 2013 financial results with…

AstraZenecaBrilintaByettaEuropeFinancialOnglyzaPharmaceuticalSymbicort

AstraZeneca sales and earning down in 1st-qtr 2013, as patent cliff bites

25-04-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reported first-quarter 2013 financial results with…

AstraZenecaFinancialPharmaceutical

Proposal to list AstraZeneca's Brilinta in New Zealand

26-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…

Asia-PacificAstraZenecaBrilintaCardio-vascularFinancialHealthcarePharmaceuticalPricingticagrelor

Positive reception for AstraZeneca recovery strategy

22-03-2013

The marathon eight-hour strategy update presented in New York on Thursday (March 21) by AstraZeneca's…

AstraZenecaFinancialPharmaceuticalResearch

Major overhaul of AstraZeneca R&D sites, and HQ move, will see 1,600 job cuts

19-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN), which is struggling with recent research disappointments…

AstraZenecaFinancialManagementPharmaceuticalResearch

AstraZeneca 2012 results continue to suffer from generic competition

31-01-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that, for full year 2012, revenues…

AstraZenecaFinancialPharmaceutical

Positive outlook for Hutchison China MediTech, say analysts

21-01-2013

Analysts at Panmure Gordon & Co say they remain buyers of Hutchison China MediTech (LSE: HCM), which…

AstraZenecaFinancialHutchison MediTechLicensingPharmaceuticalvolitinib

AstraZeneca management shakeup sign of major restructuring leading to stock recovery, say analysts

17-01-2013

The management changes at Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this week do not…

AstraZenecaBrilintaBriliqueFinancialManagementMergers & AcquisitionsPharmaceuticalShire

1 to 25 of 51 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top